KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual ObligationsEmployee StatisticsGross Margin %Gross Margin Annual %Gross ProfitIncome Before Income TaxesInventoriesNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Operating Costs & ExpensesOpex & Costs As A % Of RevenueProperty, Plant And Equipment, Net By Geography AnnualProperty, Plant & Equipment (Gross)Revenue By Business VerticalRevenue By Business Vertical %Revenue By Business Vertical AnnualRevenue By Business Vertical Annual %Revenue By Major Customers AnnualRevenue By Major Customers Annual %Revenue By ProductRevenue By Product AnnualRevenue By Product Annual %Revenue By RegionRevenue By Region %Revenue By Region AnnualRevenue By Region Annual %Revenue By Therapeutic AreaRevenue By Therapeutic Area Annual
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Gilead Sciences (GILD) Gross Profit (2009 - 2026)

Gilead Sciences posted quarterly Gross Profit of $5.5 billion for Q1 2026, up 7.57% year-on-year from $5.1 billion in Q1 2025, and down 12.47% on a QoQ basis from $6.3 billion in Q4 2025.

Gilead Sciences (GILD) has 18 years of Gross Profit data on file, last reported at $5.5 billion in Q1 2026.

  • For the quarter ending Q1 2026, Gross Profit rose 7.57% year-over-year to $5.5 billion; the trailing twelve-month figure through Mar 2026 stood at $23.6 billion (up 4.89% YoY), and the FY2025 full-year result was $23.2 billion, up 3.14% from the prior year.
  • Gross Profit for Q1 2026 stood at $5.5 billion, down from $6.3 billion in the prior quarter.
  • Across five years, Gross Profit topped out at $6.3 billion in Q4 2025 and bottomed at $4.8 billion in Q2 2022.
  • The 5-year median for Gross Profit is $5.5 billion (2023), against an average of $5.5 billion.
  • The widest annual swing landed in 2022, when Gross Profit grew 29.8%; it then declined 16.17% in 2023.
  • A 5-year view of Gross Profit shows it stood at $6.0 billion in 2022, then slipped by 16.17% to $5.0 billion in 2023, then gained by 19.19% to $6.0 billion in 2024, then gained by 5.23% to $6.3 billion in 2025, then dropped by 12.47% to $5.5 billion in 2026.
  • The last three Gross Profit figures came in at $5.5 billion (Q1 2026), $6.3 billion (Q4 2025), and $6.2 billion (Q3 2025), per Business Quant data.